

Sandrine A Urwyler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9123236/publications.pdf>

Version: 2024-02-01

21
papers

719
citations

840776

11
h-index

752698

20
g-index

22
all docs

22
docs citations

22
times ranked

1255
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2015, 385, 1511-1518.	13.7	326
2	Prognostic Value of Copeptin. <i>Stroke</i> , 2010, 41, 1564-1567.	2.0	86
3	A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 615-624.	6.1	51
4	Copeptin concentrations during psychological stress: the PsyCo study. <i>European Journal of Endocrinology</i> , 2014, 171, 737-742.	3.7	50
5	Copeptin as a stress marker prior and after a written examination – the CoEXAM study. <i>Stress</i> , 2015, 18, 134-137.	1.8	46
6	IL-1 Antagonism in Men With Metabolic Syndrome and Low Testosterone: A Randomized Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3466-3476.	3.6	27
7	IL (Interleukin)-1 Receptor Antagonist Increases Ang (Angiotensin [1 ^{–7}]) and Decreases Blood Pressure in Obese Individuals. <i>Hypertension</i> , 2020, 75, 1455-1463.	2.7	22
8	Interleukin-1 Antagonism Decreases Cortisol Levels in Obese Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1712-1718.	3.6	20
9	Copeptin levels and commonly used laboratory parameters in hospitalised patients with severe hypernatraemia - the –Co-MED study–. <i>Critical Care</i> , 2018, 22, 33.	5.8	19
10	Plasma Apelin Concentrations in Patients With Polyuria-Polydipsia Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1917-1923.	3.6	15
11	Cytokines and Cortisol – predictors of treatment response to corticosteroids in community-acquired pneumonia?. <i>Journal of Internal Medicine</i> , 2019, 286, 75-87.	6.0	11
12	Effects of interleukin-1 antagonism on cortisol levels in individuals with obesity: a randomized clinical trial. <i>Endocrine Connections</i> , 2019, 8, 701-708.	1.9	10
13	Influence of Prednisone on Inflammatory Biomarkers in Community-acquired Pneumonia: Secondary Analysis of a Randomized Trial. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1406-1414.	2.0	9
14	Effects of oral macimorelin on copeptin and anterior pituitary hormones in healthy volunteers. <i>Pituitary</i> , 2021, 24, 555-563.	2.9	5
15	Oxytocin levels in response to pituitary provocation tests in healthy volunteers. <i>European Journal of Endocrinology</i> , 2021, 185, 355-364.	3.7	5
16	Comparison of 1 [–] mg versus 2 [–] mg Dexamethasone Suppression Test in Patients with Obesity. <i>Hormone and Metabolic Research</i> , 2017, 49, 854-859.	1.5	4
17	Cosyntropin testing does not predict response to glucocorticoids in community-acquired pneumonia in a randomized controlled trial. <i>Clinical Endocrinology</i> , 2019, 91, 374-382.	2.4	4
18	The role of IL-1 in the regulation of copeptin in patients with metabolic syndrome. <i>Endocrine Connections</i> , 2020, 9, 715-723.	1.9	4

#	ARTICLE	IF	CITATIONS
19	The effect of glucose dynamics on plasma copeptin levels upon glucagon, arginine, and macimorelin stimulation in healthy adults. <i>Pituitary</i> , 2022, 25, 636-644.	2.9	4
20	Effects of interleukin-1 antagonism and corticosteroids on fibroblast growth factor-21 in patients with metabolic syndrome. <i>Scientific Reports</i> , 2021, 11, 7911.	3.3	1
21	Oxytocin Levels in Response to Pituitary Provocation Tests in Healthy Volunteers. <i>Journal of the Endocrine Society</i> , 2021, 5, A631-A631.	0.2	0